Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTRISIN versus SULPHRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTRISIN versus SULPHRIN.
AZO GANTRISIN vs SULPHRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Its active sulfide metabolite is responsible for therapeutic effects.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
1-2 tablets (500-1000 mg paracetamol, 65-130 mg caffeine) orally every 4-6 hours as needed, not exceeding 8 tablets (4000 mg paracetamol) per day for adults.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on CrCl.
2-3 hours; clinically, hepatic impairment may prolong to 5-10 hours requiring dose adjustment
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Renal: 85-90% as glucuronide and sulfate conjugates, 5-10% unchanged; biliary/fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic